NCT07196722 - A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease | Biotech Hunter

Enrollment

1,092

Participants

Timeline

Start Date

October 3, 2025

Primary Completion Date

September 19, 2028

Study Completion Date

October 6, 2032

Conditions

Crohn Disease

Interventions

DRUG

Icotrokinra

Icotrokinra will be administered orally, daily.

DRUG

Placebo

Matching placebo will be administered orally, daily.

Trial Locations (9)

10075

RECRUITING

New York Gastroenterology Associates, New York

23320

SUSPENDED

Gastroenterology Associates of Tidewater, Chesapeake

44145

SUSPENDED

Gastro Intestinal Research Institute of Northern Ohio LLC, Westlake

75701

SUSPENDED

Tyler Research Institute, LLC, Tyler

92805

RECRUITING

Clinnova Research, Anaheim

17110-3673

RECRUITING

Susquehanna Research Group, Harrisburg

02905

SUSPENDED

University Gastroenterology, Providence

892-0843

RECRUITING

Kagoshima IBD Gastroenterology Clinic, Kagoshima

861-8520

RECRUITING

Japanese Red Cross Kumamoto Hospital, Kumamoto

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY